U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07268599) titled 'Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon' on Nov. 21.
Brief Summary: To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS). The primary aim is to characterize the rapidity of symptomatic relief in moderate to severe dry eye disease (DED), with attention to short-term therapy.
Study Start Date: Nov. 24
Study Type: OBSERVATIONAL
Condition:
Dry Eye Disease (DED)
Intervention:
DRUG: Acoltremon
Patients will administer Acoltremon 0.003% as per labeled directions. Assessments with the Ocular Surfa...